HomeCompareCKOCF vs PFE

CKOCF vs PFE: Dividend Comparison 2026

CKOCF yields 3.08% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $22.6K in total portfolio value· pulled ahead in Year 9
10 years
CKOCF
CKOCF
● Live price
3.08%
Share price
$27.11
Annual div
$0.83
5Y div CAGR
7.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$856.48
Full CKOCF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CKOCF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKOCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKOCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKOCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKOCF
Annual income on $10K today (after 15% tax)
$261.59/yr
After 10yr DRIP, annual income (after tax)
$728.01/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,591.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKOCF + PFE for your $10,000?

CKOCF: 50%PFE: 50%
100% PFE50/50100% CKOCF
Portfolio after 10yr
$38.2K
Annual income
$13,557.60/yr
Blended yield
35.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CKOCF
No analyst data
Altman Z
4.6
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKOCF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKOCFPFE
Forward yield3.08%6.13%
Annual dividend / share$0.83$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7.7%13.2%
Portfolio after 10y$26.9K$49.6K
Annual income after 10y$856.48$26,258.71
Total dividends collected$5.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CKOCF vs PFE ($10,000, DRIP)

YearCKOCF PortfolioCKOCF Income/yrPFE PortfolioPFE Income/yrGap
1$11,031$331.45$9,153$693.39+$1.9KCKOCF
2$12,172$368.03$8,593$849.25+$3.6KCKOCF
3$13,432$408.73$8,336$1,066.78+$5.1KCKOCF
4$14,827$454.01$8,437$1,384.80+$6.4KCKOCF
5$16,369$504.42$9,013$1,875.40+$7.4KCKOCF
6$18,075$560.53$10,306$2,680.72+$7.8KCKOCF
7$19,964$623.01$12,820$4,101.38+$7.1KCKOCF
8$22,054$692.60$17,673$6,826.70+$4.4KCKOCF
9← crossover$24,368$770.12$27,543$12,591.86$3.2KPFE
10$26,930$856.48$49,560$26,258.71$22.6KPFE

CKOCF vs PFE: Complete Analysis 2026

CKOCFStock

Chudenko Corporation operates as an equipment engineering company in Japan. It undertakes electrical works, such as light/outlet, image/sound/TV/broadcast, power receiving/transforming, and plant equipment works; energy-related works comprising wind/solar power generation, cogeneration, energy-saving power, and private power generation system works; and environment-related works, including recycling and heat storage system works. The company also undertakes electric line/distribution line/leading wire/underground line works; and office/household water and sewerage, and industrial water and sewerage facilities works, as well as constructs, maintains, and repairs roads and architecture. In addition, it is involved in the Internet/Intranet, CATV/community wireless system/telephone, LAN, optical and mobile communication, and OA floor equipment, as well as system integration and integrated information wiring works; air-conditioning/cooling, heating/water supply, drainage/sanitation/environment equipment, and clean room system works; and fire-alarm, theft monitoring/alarm, and firefighting/evacuation guidance equipment works. Further, the company engages in building equipment renewal and housing renovation works, as well as pylon works; designs, produces, sells, repairs, installs, and maintains electrical equipment, such as distribution boards, supervisory panels, control boards, power source equipment, communication devices, heavy current devices, various measuring devices, and others; and plans, develops, sells, rents, operates, and maintains software and information processing systems. Additionally, it provides consulting and maintenance services consisting of energy saving diagnosis/support services, as well as disaster prevention and firefighting equipment inspection services. The company was founded in 1944 and is headquartered in Hiroshima, Japan.

Full CKOCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CKOCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKOCF vs SCHDCKOCF vs JEPICKOCF vs OCKOCF vs KOCKOCF vs MAINCKOCF vs JNJCKOCF vs MRKCKOCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.